Contracts › 75A50124C00053
75A50124C00053: Ad Astra Diagnostics, Inc. (PLUS) &D for Clia-Waived Ubiquitous Early Sepsis Detection, Severity in Ambulance, Pre-Hospital, Post- Discharge Aoi #02+: Infection Severity and Solving Sepsis
Awarded to Ad Astra Diagnostics, Inc. by Office of Assistant Secretary for Preparedness and Response.
$6.7Mobligated
$14.3Mpotential value
17 December 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50124C00053 |
|---|---|
| Awardee | Ad Astra Diagnostics, Inc. |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN13 Health R&D Services; Health Care Services; Experimental Development |
| Place of performance | NC |
| Offers received | 99 |
| Period of performance | 22 September 2024 to 17 December 2028 |
| Potential end | 17 December 2028 |
| Estimated recompete solicitation | ~Q2 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record